Table 5A. Progression-free survival in patients with SD as best response.
| Patient number | Tumour type | Dose level (mg m−2) (day 1/2/3) | Progression-free survival (days) |
|---|---|---|---|
| 01–002 | Prostate | 1.2 | 112 |
| 01–006 | Cholangiocarcinoma | 2.5 | 89 |
| 01–010 | Colorectal | 5 | 112 |
| 01–012 | Non-small cell lung | 10 | 52a |
| 01–017 | Pancreas | 40 | 57a |
| 01–022 | Adenocarcinoma | 66.8 | 63a |
| 03–029 | Prostate | 88 | 119 |
| 03–031 | Endometrial | 40/66.8/66.8 | 77a |
| 03–036 | Hepatocellular | 40/66.8/66.8 | 336 |
| 03–037 | Prostate | 40/66.8/66.8 | 121a |
| 03–043 | Hepatocellular | 40/66.8/66.8 | 133 |
| 03–044 | Hepatocellular | 40/66.8/66.8 | 277a |
Abbreviation: SD=stable disease.
a
Censored observation.